Bank of New York Mellon Corp Sells 75,482 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Bank of New York Mellon Corp lowered its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 8.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 850,636 shares of the company's stock after selling 75,482 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.22% of Recursion Pharmaceuticals worth $5,750,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals in the fourth quarter worth approximately $26,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after purchasing an additional 4,948 shares in the last quarter. KBC Group NV grew its holdings in Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after purchasing an additional 3,377 shares during the period. Colonial River Investments LLC purchased a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $68,000. Finally, Centaurus Financial Inc. bought a new position in shares of Recursion Pharmaceuticals in the third quarter worth about $71,000. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Price Performance

Shares of RXRX traded down $0.10 during midday trading on Thursday, hitting $6.49. 12,757,084 shares of the company traded hands, compared to its average volume of 10,435,904. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.60 and a 52 week high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a 50 day moving average of $7.49 and a 200-day moving average of $7.00. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of -4.25 and a beta of 0.85.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analysts' expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's quarterly revenue was down 57.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.42) EPS. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Finally, Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $8.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.